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Introduction: The proapoptotic small-molecule pan–Bcl-2 inhibi-
tor obatoclax mesylate (GX15-070) may enhance the cytotoxicity 
of chemotherapy in relapsed/refractory non–small-cell lung cancer 
(NSCLC).
Methods: Obatoclax was administered with docetaxel in patients 
with relapsed or refractory NSCLC— docetaxel as a 1-hour infusion 
on day 1 and obatoclax as a 24-hour infusion on days 1 and 2—every 
3 weeks for up to eight cycles. Four dose levels were evaluated in 
phase 1 (level 1: docetaxel 55 mg/m2 × 1 and obatoclax 30 mg × 2; 
levels 2–4: docetaxel 75 mg/m2 and obatoclax 30 mg, 45 mg, or 60 mg 
× 2) to identify dose-limiting toxicity and a phase 2 dose. In phase 2, 
response and tolerability were evaluated.
Results: Eighteen patients were included in phase 1. Two dose-lim-
iting toxicities occurred during cycle 1: one febrile neutropenia each 
at dose levels 3 and 4. Maximum tolerated dose was not reached; 
32 patients (including 3 from phase 1) were treated in phase 2 with 
docetaxel 75 mg/m2 and obatoclax 60 mg (median 2 cycles). Three 
patients (11%) had partial responses in phase 2; two demonstrated 
stable disease lasting 12 weeks or more. Median duration of response 
was 4.8 months. Overall, median progression-free survival was 1.4 
months. Neutropenia (31%), febrile neutropenia (16%), and dyspnea 
(19%) were the most common grade 3/4 adverse events observed.
Conclusions: Combined obatoclax mesylate plus docetaxel is toler-
able in patients with NSCLC, but response was minimal and neutro-
penia was a common adverse event.
Key Words: Non–small-cell lung cancer, Apoptosis, Maximum tol-
erated dose, Efficacy.
(J Thorac Oncol. 2014;9: 121–125)
Few effective treatments exist for patients with advanced non–small-cell lung cancer (NSCLC) who have progressed 
during or relapsed after first-line platinum-based chemother-
apy. Docetaxel is standard in the second-line NSCLC setting,1 
but the objective response rate in patients with relapsed/refrac-
tory disease is lower than 10% and median time to progres-
sion is approximately 3 months.1,2 Thus, novel agents that may 
enhance the sensitivity of NSCLC cells to taxanes are needed.
The Bcl-2 family of antiapoptotic proteins, frequently 
expressed in NSCLC cells,3 is an attractive target for inhibit-
ing tumor growth. Obatoclax mesylate modulates the Bcl-2 
protein family with antagonistic activity to Bcl-2, Bcl-xL, 
Bcl-W, and Mcl-1.4 Obatoclax has been investigated in combi-
nation with standard chemotherapy in patients with advanced 
solid tumors (including small-cell lung cancer).5–7 We evalu-
ated the safety and tolerability of obatoclax in combination 
with docetaxel in patients with advanced NSCLC who pro-
gressed after prior chemotherapy.
PATIENTS AND METHODS
An open-label, phase 1/2 study was conducted in 
advanced NSCLC patients who progressed after platinum-
based chemotherapy between November 2006 and November 
2008 at seven U.S. sites (clinicaltrials.gov NCT00405951). 
Patients were aged 18 years or more, with pathological con-
firmation of NSCLC including measurable disease using 
Response Evaluation Criteria in Solid Tumors v1.0.8 In phase 1, 
patients progressing after one or more platinum-based regi-
men or paclitaxel were enrolled. In phase 2, patients were per-
mitted only one prior platinum-based regimen for advanced 
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or metastatic disease; prior paclitaxel, erlotinib, or gefitinib 
was permitted. In both phases, prior treatment must have been 
stopped 14 days or more before enrollment, and associated 
adverse effects resolved to grade 1 or lower. Other inclusion 
criteria were absolute neutrophil count 1500/mm3 or more, 
platelet count 100,000/mm3 or more, adequate liver and renal 
function, and Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1.
Phase 1 evaluated the dose-limiting toxicity (DLT) and 
maximum tolerated dose (MTD) of obatoclax plus docetaxel. 
Four dose levels were planned (Table 1). If no DLT occurred at 
the highest planned dose level and MTD was not determined, 
that dose was used in phase 2. DLTs were defined as grade 3 or 
higher neurologic adverse event (AE), grade 4 febrile neutro-
penia or thrombocytopenia, grade 4 neutropenia for 7 days or 
more, and other grade 3/4 nonhematologic toxicity not ame-
liorated by symptom-directed therapy. If DLTs occurred, treat-
ment was modified. Once the DLTs were resolved to grade 2 
or lower, the patient resumed treatment with appropriate dose 
reductions. Docetaxel was discontinued in patients who devel-
oped grade 2 or higher peripheral neuropathy. Docetaxel dose 
was reduced for DLTs attributed to myelosuppression; for all 
other DLTs, the obatoclax dose was reduced to the next lowest 
dose level. Treatment was discontinued if toxicity occurred at 
the lowest dose level, recurred after dose reduction, or if treat-
ment was delayed for more than 28 days.
Phase 2 assessed the efficacy, safety, and pharmacoki-
netic properties of obatoclax in combination with docetaxel. 
Patients received obatoclax plus docetaxel until disease pro-
gression, unacceptable toxicity, or investigator/patient deci-
sion to stop treatment. A two-stage design was used to detect 
an objective response rate of 20% or more at 80% power and an 
α level of 0.05. Efficacy was evaluated per investigator review 
by using Response Evaluation Criteria in Solid Tumors v1.0.8 
AEs were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events v3.0.9
Obatoclax plasma concentrations were assessed during 
cycle 1 of each dose level. Samples were drawn at 1, 3, 24, 47, 
and 49 hours, timed from the start of the obatoclax infusion. 
Peak serum concentration (C
max
) and area under the plasma 
concentration-time curve (AUC
0–49h
) were determined for each 
dose level.
The safety population included all patients receiving 
obatoclax. The efficacy population included patients who 
received the phase 2 recommended dose, had at least one post-
baseline assessment, and received no more than one platinum-
containing regimen. Time-to-event data were estimated using 
Kaplan–Meier methods with associated two-sided 95% confi-
dence intervals (CIs).
The study was conducted in accordance with the 
Declaration of Helsinki and complied with local, state, and 
federal regulations. An institutional review board or indepen-
dent ethics committee reviewed and approved the protocol and 
all patients provided written informed consent.
RESULTS
Phase 1 Study
Eighteen patients were enrolled (Fig. 1A). All patients 
received prior therapy for NSCLC (Supplementary Table 1, 
Supplementary Digital Content 1, http://links.lww.com/
JTO/A488). No DLTs were observed at dose levels 1 and 2 
(Table 1). At both dose levels 3 and 4, one patient each expe-
rienced grade 4 febrile neutropenia in cycle 1; these groups 
were expanded and no further DLTs were reported. The MTD 
was not reached; consequently, dose level 4 was selected for 
phase 2 evaluation.
Among phase 1 patients, one patient at dose level 1 
and two patients at dose level 4 achieved partial response 
(PR); stable disease was best response in 11 of 18 patients. 
Neutropenia was the most common grade 3/4 AE observed 
(56%); three patients (17%) had febrile neutropenia (Table 
3). Twelve patients (67%) experienced one or more psychi-
atric event, all grade of 2 or lower. Six patients experienced 
treatment-related serious AEs, including febrile neutropenia 
(n=3), grade 3 vomiting (n=1) leading to discontinuation, 
grade 4 neutropenia with grade 2 anemia (n=1), and grade 1 
confusional state (n=1).
TABLE 1.  Phase 1 Dose Escalation, Drug Exposure, and Summary of Dose-Limiting Toxicities (N = 18)
Dose Level Docetaxela Obatoclaxb n
Dose-Limiting 
Toxicities
Median Number of 
Cyclesc Administered 
(Range)
Median
Number of 
Treatment Days 
(Range)
1 55 mg/m2d 30 mg × 2 days 3 Nonee 3
(2–8)
59 
(23–151)
2 75 mg/m2 30 mg × 2 days 3 Nonee 4
(2–6)
80
(24–108)
3 75 mg/m2 45 mg × 2 days 6f 1 febrile neutropenia 5
(2–8)
87
(24–150)
4 75 mg/m2 60 mg × 2 days 6f 1 febrile neutropenia 3
(2–10)
46
(3- 199)
aIntravenous infusion over 1 hour on day 1.
bIntravenous infusion over 48 hours on days 1 and 2. 
cA cycle constituted 21 days.
dInitial dose of docetaxel was 55 mg/m2 because obatoclax may inhibit the CYP3A4 isoform responsible for docetaxel metabolism. 
eReported during cycle 1. 
fGroup was expanded to six patients because of dose-limiting toxicities reported in first group of three.
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Phase 2 Study
Thirty-two patients were enrolled, including three 
patients from phase 1 who met phase 2 enrollment cri-
teria (Fig. 1B). Supplementary Table 1 (Supplementary 
Digital Content 1, http://links.lww.com/JTO/A488) pres-
ents demographics and baseline characteristics. Patients 
received a median of two treatment cycles (range, 
1–12); median dose/cycle of obatoclax was 120 mg 
(range, 18.7–120 mg) and of docetaxel was 75 mg/m2  
(range, 55–75 mg/m2).
The efficacy population included 27 patients (Fig. 1B). 
Table 2 summarizes best responses to treatment. In the 
first stage, one patient (9%) included from phase 1 had a 
PR and the trial proceeded to stage 2. In stage 2, two addi-
tional patients (13%) achieved PR, and overall response 
rate was 11% (95% CI 2.35–29.16). No complete responses 
were reported. All patients with PR had stage IV disease. 
Median duration of response was 4.8 months (95% CI 
4.4–5.2) in patients with PR (n=3) and 5.3 months (95% 
CI 4.1–7.1) in patients with PR or stable disease (n=5). 
Overall, median progression-free survival (PFS) was 1.4 
months (95% CI 1.2–3.4).
FIGURE 1.  Patient enrollment and disposition in phase 1 (A) and phase 2 (B). D, docetaxel; O, obatoclax: PR, partial response.
TABLE 2.  Best Response to Treatment with Obatoclax Plus 
Docetaxel (Phase 2)
Obatoclax 60 mg × 2 days +  
Docetaxel 75 mg/m2
Stage 1a n = 11 Stage 2 n = 16 Total N = 27
Best response, n (%)
Complete response 0 0 0
Partial response 1 (9.1) 2 (12.5) 3 (11.1)
Stable disease ≥12 weeks 1 (9.1) 1 (6.3) 2 (7.4)
Stable disease <12 weeks 2 (18.2) 5 (31.3) 7 (25.9)
Progressive disease 7 (63.6) 8 (50.0) 15 (55.6)
Overall response, n (%) 1 (9.1) 2 (12.5) 3 (11.1)
aIncludes one phase 1 patient with partial response.
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Twenty-eight patients (88%) experienced one or more 
nervous system disorder or psychiatric disorder related adverse 
events (Table 3), most of which were of grade 2 or lesser. One 
patient each discontinued treatment because of grade 4 cere-
bral ischemia, grade 3 agitation and hallucination, and grade 
3 hallucination; patients with hallucinations had either prior or 
current secondary brain metastases. Treatment delays occurred 
in three patients because of grade 3 cough and dyspnea, grade 
3 anasarca, and grade 1 pulmonary infiltrate. Docetaxel dose 
was reduced (75 mg/m2 to 55 mg/m2) in five patients because 
of grade 3/4 neutropenia or febrile neutropenia.
Six patients experienced treatment-related serious AEs, 
including febrile neutropenia (n=4), grade 3 leukopenia (n=1), 
and grade 3 hallucination (n=1). Three patients experiencing 
febrile neutropenia were treated with filgrastim; recovery from 
neutropenia occurred at a median of 4 days (range, 2–6 days). 
Leukopenia resolved without intervention or dose adjustment. 
Study treatment was stopped in the patient experiencing hal-
lucinations, which resolved without further intervention.
As of the last follow-up assessment, 11 of 32 patients 
(34%) had died. Two deaths, attributed to AEs (1 broncho-
pneumonia, 1 pneumonia), occurred more than 30 days after 
the last dose of study treatment and were not considered 
treatment-related. Seven deaths were attributed to disease pro-
gression or lung cancer, and causes of death for two patients 
were unknown.
Pharmacokinetics
Samples from 17 phase 1 patients (across all dose lev-
els) and 30 phase 2 patients were analyzed. Supplementary 
Table 2 (Supplementary Digital Content 2, http://links.lww.
com/JTO/A489) summarizes pharmacokinetic parameters for 
obatoclax.
DISCUSSION
We evaluated the MTD, safety, pharmacokinetics, and 
efficacy of the pan–Bcl-2 inhibitor obatoclax in combination 
with docetaxel in patients with relapsed or refractory NSCLC. 
AEs were consistent with those previously reported; myelo-
suppression was frequent but expected with docetaxel and 
was manageable with dose reduction of docetaxel. No hema-
tologic AEs led to dose delay or discontinuation of obatoclax 
or docetaxel.
Transient neurologic toxicities, including dizziness, 
somnolence, ataxia, and euphoric mood, were observed and 
TABLE 3.  Adverse Events Occurring in ≥10% of Patients Treated with Obatoclax and Docetaxel in Phase 1 and Phase 2
Treatment-Emergent Adverse 
Events, n (%)
Phase 1
N = 18
Phase 2
N = 32
All Grades Grade 3 or 4 All Grades Grade 3 or 4
≥1 Event 18 (100.0) 15 (83.3) 32 (100.0) 20 (62.5)
Hematologic
  Anemia
  Neutropenia
  Febrile neutropenia
10 (55.6)
10 (55.6)
3 (16.7)
 
—
10 (55.6)
3 (16.7)
15 (46.9)
12 (37.5)
5 (15.6)
2 (6.3)
10 (31.3)
5 (15.7)
Nonhematologic
  Fatigue
  Nausea
  Dyspnea
  Alopecia
  Anorexia
  Dizziness
  Cough
  Constipation
  Insomnia
  Diarrhea
  Vomiting
  Mucosal inflammation
  Flushing
  Ataxia
  Pharyngolaryngeal pain
  Dehydration
  Peripheral edema
  Dysgeusia
  Headache
  Peripheral neuropathy
  Somnolence
  Confusional state
  Euphoric mood
  Back pain
  Chills
  Pyrexia
  Anxiety
  Hallucinations
9 (50)
7 (38.9)
3 (16.7)
11 (61.1)
5 (27.8)
2 (11.1)
2 (11.1)
3 (16.7)
—
3 (16.7)
3 (16.7)
—
2 (11.1)
3 (16.7)
7 (38.9)
5 (27.8)
—
2 (11.1)
2 (11.1)
—
—
4 (22.2)
4 (22.2)
3 (16.7)
2 (11.1)
3 (16.7)
—
—
—
—
2 (11.1)
—
—
—
—
—
—
—
1 (5.6)
—
—
—
—
—
—
—
—
—
—
—
—
1 (5.6)
—
—
—
—
19 (59)
17 (53)
16 (50)
14 (44)
13 (41)
11 (34)
9 (28)
8 (25)
8 (25)
7 (22)
7 (22)
7 (22)
7 (22)
6 (19) 
6 (19)
6 (19)
5 (16)
5 (16)
5 (16)
5 (16)
5 (16)
5 (16)
5 (16)
5 (16)
4 (13)
4 (13)
4 (13)
4 (13)
2 (6)
—
6 (19)
—
— 
— 
1 (3) 
—
—
—
1 (3)
1 (3)
—
—
—
—
—
—
—
—
—
—
—
2 (6)
—
—
—
2 (6)
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anticipated based on previous studies of obatoclax.5–7,10–14 
They were considered tolerable in this study. Grade 3 hallu-
cinations leading to treatment discontinuation in two patients 
(1 patient had brain metastasis) were resolved the following 
day without treatment in one patient and on the day of onset 
with haloperidol treatment in the second patient.
Limited efficacy in patients with recurrent NSCLC was 
observed at the dose selected for phase 2 evaluation (obato-
clax 60 mg×2 days plus docetaxel 75 mg/m2) compared with 
the response rate in phase 1. It should be noted that patients 
in the 2 phases had different baseline characteristics (e.g., 
Eastern Cooperative Oncology Group performance status) 
that may affect treatment exposure. The efficacy of this regi-
men was similar in terms of response rate but inferior to pre-
viously reported results for single-agent docetaxel except 
with regard to PFS and duration of response.2,15 The MTD for 
this combination was not reached; efficacy may increase at 
higher dose levels and by extending treatment exposure, as all 
patients with PR had received six or more cycles.
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